BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 336 filers reported holding BIO-TECHNE CORP in Q3 2019. The put-call ratio across all filers is 5.05 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $44,492,919 | -17.7% | 653,635 | -1.3% | 1.78% | -12.5% |
Q2 2023 | $54,056,529 | +39.3% | 662,214 | +26.6% | 2.04% | +2.0% |
Q1 2023 | $38,815,170 | -10.5% | 523,186 | -0.0% | 2.00% | -17.8% |
Q4 2022 | $43,363,065 | +18.3% | 523,203 | +305.3% | 2.43% | +8.9% |
Q3 2022 | $36,661,000 | +13.4% | 129,085 | +38.4% | 2.23% | -10.3% |
Q2 2022 | $32,330,000 | -23.1% | 93,267 | -3.9% | 2.49% | -4.3% |
Q1 2022 | $42,016,000 | -15.0% | 97,025 | +1.5% | 2.60% | -9.4% |
Q4 2021 | $49,456,000 | +12.0% | 95,597 | +4.9% | 2.87% | -1.8% |
Q3 2021 | $44,169,000 | +8.9% | 91,152 | +1.2% | 2.92% | +9.2% |
Q2 2021 | $40,569,000 | +19.3% | 90,102 | +1.2% | 2.68% | +7.6% |
Q1 2021 | $33,995,000 | +23.1% | 89,007 | +2.3% | 2.49% | +16.6% |
Q4 2020 | $27,625,000 | +21.7% | 86,993 | -5.1% | 2.13% | +6.6% |
Q3 2020 | $22,708,000 | -5.1% | 91,662 | +1.1% | 2.00% | -13.0% |
Q2 2020 | $23,931,000 | +68.2% | 90,624 | +20.8% | 2.30% | +5.8% |
Q1 2020 | $14,226,000 | -24.2% | 75,024 | -12.3% | 2.17% | -9.3% |
Q4 2019 | $18,771,000 | +190.9% | 85,511 | +159.3% | 2.40% | +29.0% |
Q3 2019 | $6,452,000 | -3.1% | 32,977 | +3.3% | 1.86% | -4.0% |
Q2 2019 | $6,658,000 | +9.9% | 31,932 | +4.7% | 1.94% | +5.2% |
Q1 2019 | $6,057,000 | +43.4% | 30,507 | +4.6% | 1.84% | +23.7% |
Q4 2018 | $4,223,000 | +2.4% | 29,177 | +38.7% | 1.49% | -41.0% |
Q3 2018 | $4,123,000 | +2.9% | 21,030 | -22.4% | 2.52% | +81.3% |
Q2 2018 | $4,008,000 | +165.4% | 27,110 | +171.1% | 1.39% | +155.0% |
Q1 2018 | $1,510,000 | – | 10,000 | – | 0.54% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 46,500 | $13,206,000 | 5.33% |
Montanaro Asset Management Ltd | 101,950 | $28,954,000 | 4.43% |
Jackson Square Partners, LLC | 521,991 | $148,245,000 | 3.89% |
Sandhill Capital Partners LLC | 119,671 | $33,987,000 | 3.88% |
STONE RUN CAPITAL, LLC | 22,055 | $6,264,000 | 3.38% |
Ownership Capital B.V. | 610,466 | $173,372,000 | 3.35% |
Brown Capital Management | 823,303 | $233,818,000 | 3.28% |
DF DENT & CO INC | 671,348 | $190,663,000 | 2.94% |
Westwind Capital | 27,931 | $7,932,000 | 2.78% |
MAIRS & POWER INC | 673,620 | $191,308,000 | 2.41% |